β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 3, 2013, Pages 388-397

  Venishetty, Vinay Kumar ^a,b   Samala, Ramakrishna ^b   Komuravelli, Rojarani ^c   Kuncha, Madhusudana ^a   Sistla, Ramakrishna ^a   Diwan, Prakash V ^a,d  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c KAKATIYA UNIVERSITY   (India)

^d ANURAG UNIVERSITY   (India)

Author keywords

Beta Hydroxybutyric acid; Docetaxel; Ketone bodies; Pharmacokinetics; Solid lipid nanoparticles; Stearylamine

Indexed keywords

DOCETAXEL; HYDROXYBUTYRIC ACIDS; IMMUNOCYTOCHEMISTRY; KETONE BODIES; MONOCARBOXYLIC ACID TRANSPORTERS; NEUROLOGICAL DISEASE; SOLID LIPID NANOPARTICLE (SLN); STEARYLAMINE;

CYTOTOXICITY; DISEASE CONTROL; DRUG DELIVERY; ENDOTHELIAL CELLS; GRAFTING (CHEMICAL); KETONES; PHARMACOKINETICS;

NANOPARTICLES;

3 HYDROXYBUTYRIC ACID; BETRELIESOXYBUTYRIC ACID; BUTYRIC ACID DERIVATIVE; DOCETAXEL; MONOCARBOXYLATE TRANSPORTER 1; OCTADECYLAMINE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PARTICLE SIZE;

3-HYDROXYBUTYRIC ACID; AMINES; ANIMALS; AREA UNDER CURVE; BRAIN; CELL DEATH; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENDOTHELIAL CELLS; HUMANS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MONOCARBOXYLIC ACID TRANSPORTERS; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; PHOTOELECTRON SPECTROSCOPY; POWDERS; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; SYMPORTERS; TAXOIDS; X-RAY DIFFRACTION;

EID: 84875483025     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.08.004     Document Type: Article

References (33)

1. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007, 2(12):751-760.
2. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9(8):615-627.
3. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008, 127(2):97-109.
4. Joshi M.D., Müller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009, 71(2):161-172.
5. Hainsworth J.D. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004, 9(5):538-545.
6. Yvon A.M., Wadsworth P., Jordan M.A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999 Apr, 10(4):947-959.
7. Owen O.E., Morgan A.P., Kemp H.G., Sullivan J.M., Herrera M.G., Cahill G.F. Brain metabolism during fasting*. J Clin Invest 1967, 46(10):1589-1595.
8. Maurer M.H., Canis M., Kuschinsky W., Duelli R. Correlation between local monocarboxylate transporter 1 (MCT1) and glucose transporter 1 (GLUT1) densities in the adult rat brain. Neurosci Lett 2004, 355(1-2):105-108.
9. Hawkins R.A., Williamson D.H., Krebs H.A. Ketone-body utilization by adult and suckling rat brain in vivo. Biochem J 1971, 122(1):13-18.
10. Pellerin L., Pellegri G., Martin J.-L., Magistretti P.J. Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc Natl Acad Sci U S A 1998, 95(7):3990-3995.
11. Gerhart D.Z., Enerson B.E., Zhdankina O.Y., Leino R.L., Drewes L.R. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am J Physiol Endocrinol Metab 1997, 273(1):E207-E213.
12. Pierre K., Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 2005, 94(1):1-14.
13. Pardridge W.M. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 1983, 63(4):1481-1535.
14. Tildon J.T., Roeder L.M. Transport of 3-hydroxy[3-14C]butyrate by dissociated cells from rat brain. Am J Physiol 1988, 255(2 Pt 1):C133-C139.
15. Hasselbalch S.G., Knudsen G.M., Jakobsen J., Hageman L.P., Holm S., Paulson O.B. Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans. Am J Physiol Endocrinol Metab 1995, 268(6):E1161-E1166.
16. Trotta M., Debernardi F., Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003, 257(1-2):153-160.
17. Andersen A., Warren D.J., Brunsvig P.F., Aamdal S., Kristensen G.B., Olsen H. High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. BMC Clin Pharmacol 2006, 6:2.
18. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004, 95(3):627-638.
19. Kumar V.V., Chandrasekar D., Ramakrishna S., Kishan V., Rao Y.M., Diwan P.V. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 2007, 335(1-2):167-175.
20. Miglietta A., Cavalli R., Bocca C., Gabriel L., Rosa Gasco M. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000, 210(1-2):61-67.
21. Kuppens I.E., van Maanen M.J., Rosing H., Schellens J.H., Beijnen J.H. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005, 19(5):355-361.
22. Pardridge W. Introduction to the blood-brain barrier 1998, Cambridge University Press, Cambridge, United Kingdom.
23. Blasberg R.G., Fenstermacher J.D., Patlak C.S. Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 1983, 3(1):8-32.
24. Kemper E.M., Verheij M., Boogerd W., Beijnen J.H., van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004, 40(8):1269-1274.
25. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000, 50(1):161-177.
26. Budhian A., Siegel S.J., Winey K.I. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007, 336(2):367-375.
27. Manjunath K., Reddy J.S., Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005, 27(2):127-144.
28. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30(2):226-232.
29. Yang S., Zhu J., Lu Y., Liang B., Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999, 16(5):751-757.
30. Miettinen S., Grenman S., Ylikomi T. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anticancer Drugs 2009, 20(4):267-276.
31. Kelly R.J., Draper D., Chen C.C., Robey R.W., Figg W.D., Piekarz R.L., et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist, Tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011, 17(3):569-580.
32. Ben Reguiga M., Bonhomme-Faivre L., Farinotti R. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. J Pharm Pharmacol 2007, 59(3):401-408.
33. Gupta Y., Jain A., Jain S.K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007, 59(7):935-940.